BRAF and colorectal cancer: For example, for common tumours such as colorectal cancer where there is an ever-expanding list of clinically relevant biomarkers (e.g., BRAF V600E, MMR, HER2, POLE, KRAS G12C, NTRK), each patient subset represents only a small proportion of the overall population.